SHORT INTEREST 9.44%
AVERAGE ANALYSTS PRICE TARGET $16.06
AVERAGE ANALYSTS RECOMMENDATION BUY
Marinus Pharmaceuticals , Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
1) Sign Up for our Free Email Newsletter @
2) Sign Up for our Free Text Message Notifications
by Texting 'GAINS' to 67076.
(*It's FREE, however Msg&Data rates may apply